1. Introduction {#s0005}
===============

Due to antiretroviral therapy (ART) advances, there has been a sharp increase in lifespan of people living with HIV (PLWH). In the past decade alone there has been a near four-fold increase in the number of PLWH over 50 years old in North America and Europe ([@bb0130]) with further increases expected by 2030 ([@bb0180]). As a result, the prevalence of age-related HIV-associated comorbidities, such as osteoporosis, is increasing ([@bb0065]).

The prevalence of osteoporosis is higher in PLWH compared to uninfected controls, and ART use also appears to contribute to BMD loss ([@bb0040]). Despite well-described observational associations, mechanisms linking HIV infection, ART treatment, and bone loss remain uncertain. However, the Wnt/β-catenin signaling pathway is a critical mediator of bone mass ([@bb0195]) that may be affected by HIV infection.

Skeletal Wnt/β-catenin signaling is regulated locally by osteocytes embedded within the bone matrix via production of sclerostin, a soluble antagonist to Wnt/β-catenin signaling ([@bb0075]; [@bb0120]; [@bb0175]). Due to potent suppression of bone formation by sclerostin, antibody-based therapeutics targeting sclerostin have been developed as bone-building osteoporosis treatments ([@bb0115]). Despite sclerostin\'s role as a bone formation antagonist, sclerostin is positively associated with BMD in many diseases ([@bb0050]; [@bb0185]; [@bb0135]; [@bb0110]; [@bb0105]; [@bb0190]). Sclerostin levels were reported to be positively associated with BMD in a cohort of PLWH ([@bb0080]). However, the previous study did not include an HIV-seronegative comparison group and thus could not assess whether the association between sclerostin and BMD is influenced by HIV-serostatus.

The goal of the current study was to determine associations between sclerostin and BMD in a cohort HIV-seropositive and HIV-seronegative women in early menopause, a population at particularly high risk for bone loss and osteoporosis. HIV-status has been reported to influence bone mass ([@bb0095]), as well as, the circulating levels of sclerostin ([@bb0015]; [@bb0150]). Additionally, ART use is associated with loss of bone mass, although the magnitude is dependent on the class of ART used ([@bb0040]). The effects of ART use on circulating sclerostin levels are not well known, although one study reported a mild increase in sclerostin after switching from tenofovir disoproxil fumarate (TDF) to abacavir ([@bb0165]), which is likely a function of the increased bone mass noted after switching off of TDF ([@bb0160]). Due to the strong associations between sclerostin and BMD and the previously reported influence of both HIV and ART on BMD, we hypothesize that the association between sclerostin and BMD are influenced by both HIV-serostatus and ART.

2. Materials and methods {#s0010}
========================

2.1. Study participants {#s0015}
-----------------------

The current musculoskeletal (MSK) study was nested within the Women\'s Interagency HIV Study (WIHS) at the Bronx, San Francisco, and Chicago sites. The WIHS is an ongoing multisite longitudinal cohort study of women with and at risk for HIV infection that has recruited in waves since its initiation in 1993. As of 2015, a total of 4982 women have been recruited to participate in the cohort ([@bb0005]). A total of 220 women (137 HIV-seropositive and 83 HIV-seronegative) were enrolled into the baseline MSK study between 2011 and 2014 and were included in this analysis. At the time of enrollment, all participants were between age 40--60, and either peri-menopausal or postmenopausal by self-report according to SWAN study definitions ([@bb0085]): early perimenopause (at least 1 menstrual period in the last 3 months with some change in the regularity over last 12 months), late perimenopause (no bleeding in 3--11 of the last 12 months), or early postmenopausal (no bleeding for \>1 but \<5 years). Since [@bb0085] found that the rate of bone loss was similar in premenopause and early perimenopause, but lower than that of late perimenopause and early postmenopause, we categorized menopausal status into those in early perimenopause and those that were in postmenopause (late peri-menopause and early postmenopause), Additional study entry criteria included weight \<264 pounds and height 6′1″ or below (due to limitations of our DXA testing), and for HIV-seropositive women, the most recent CD4 count had to be \>100 cells/μL, and ART used for the prior year without missing \>2.5 months of therapy during that year.

2.2. Bone mineral density (BMD) assessment {#s0020}
------------------------------------------

Participants underwent whole body DXA. DXA scans performed on Lunar Prodigy densitometers (GE Medical Systems, Madison WI) at all study locations. Scans were read centrally at the Image Analysis Lab (New York, NY). Height and weight were measured using a stadiometer and balance beam scale.

2.3. Blood biomarkers {#s0025}
---------------------

Blood samples were collected using sodium citrate coated tubes, separated into plasma aliquots, stored at −80 °C, then thawed and batch-analyzed at the Irving Columbia University Irving Medical Center Biomarker Laboratory and at Rush University Medical Center. We measured circulating sclerostin (TECOmedical ELISA, Sissach, Switzerland); N-terminal propeptide of procollagen type 1 (P1NP; RIA; IDS, Scottsdale, AZ); C-telopeptide of type 1 collagen (CTX, ELISA, IDS Scottsdale, AZ), tumor necrosis factor alpha (TNFα; ELISA, R&D Systems, Minneapolis, MN); and interleukin-6 (IL-6; ELISA, R&D Systems, Minneapolis, MN).

2.4. Additional participant characteristics {#s0030}
-------------------------------------------

Cumulative ART exposure was categorized by class; (protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), tenofovir disoproxil fumarate (TDF), and abacavir) use prior to MSK enrollment (in years) was determined from participant reported ART use. Body mass index (BMI) was calculated at MSK enrollment from objectively measured height and weight.

2.5. Statistical analysis {#s0035}
-------------------------

The primary outcomes of interest were areal BMD at the lumbar spine, total hip, femoral neck, distal radius and ultradistal radius, and the primary predictor of interest was circulating plasma sclerostin levels. Other covariates included age (continuous), race (Black, White, Other), WIHS study locations (Bronx, San Francisco, Chicago), menopause status at MSK enrollment, and the circulating levels of CTX and P1NP. Characteristics of HIV-seropositive vs. seronegative women were compared using exact tests for proportions and rank tests for continuous variables. Pearson\'s correlations quantified the association of sclerostin with CTX, P1NP, IL-6, and TNFα. Univariate linear regression models were fit between sclerostin and other variables of interest and BMD at each skeletal site. Hierarchical multivariate linear models were fit for each BMD site, with sclerostin as the primary predictor of interest and demographic and potential BMD-modifying variables as potential confounding variables. Due to a strong correlation between CTX and P1NP, and the significant association between CTX and sclerostin, only CTX was included in the multivariate models.

3. Results {#s0040}
==========

3.1. Participant characteristics {#s0045}
--------------------------------

The mean age was 49.3 for HIV-seronegative and 49.9 years for seropositive women. HIV seropositive and seronegative women did not statistically differ by race, study site, menopausal status at MSK enrollment, BMI, or hepatitis C infection, defined using HCV antibody and confirmed with HCV RNA ([Table 1](#t0005){ref-type="table"}). Circulating levels of inflammatory cytokines (TNFα and IL-6) did not differ by HIV-serostatus. Compared to HIV-seronegative participants, HIV-seropositive women had both significantly lower BMD at each skeletal site measured and higher plasma levels of bone remodeling biomarkers, CTX and P1NP ([Table 1](#t0005){ref-type="table"}). There were no significant differences between HIV-seropositive and HIV-seronegative women in the circulating levels of sclerostin. Circulating sclerostin was positively associated with age (Coefficient: 0.03, p = 0.002) and this relationship was not affected by HIV-serostatus.Table 1Characteristics of HIV seronegative and seropositive women.Table 1HIV uninfectedHIV infectedp-ValueSample size (n)83137Age (yr)\
\[media (Q1, Q3)\]49.3\
(43.9, 53.0)49.9\
(46.9, 53.3)0.18Race (n) White11 (13.25%)22 (16.06%)0.66 Black60 (72.29%)91 (66.42%) Other12 (14.46%)24 (17.52%)Enrollment site (n) Bronx NYC32 (38.55%)54 (39.42%)0.95 San Francisco35 (42.17%)55 (40.15%) Chicago16 (19.28%)28 (20.44%)Menopausal status (n) Premenopausal/early perimenopause34 (40.96%)46 (33.58%)0.27 Late perimenopause/post-menopausal49 (59.04%)91 (66.42%)BMI (kg/m2) \<18.5 = thin2 (2.41%)2 (1.46%)0.42 18.5--24.9 = normal13 (15.66%)33 (24.09%) 25.0--29.9 = overweight24 (28.92%)41 (29.93%) ≥20.0 = obese44 (53.01%)61 (44.53%)Hepatitis C virus infection (n) Negative62 (74.70%)91 (66.42%)0.087 Resolved infection (Ab & RNA negative)3 (3.61%)11 (8.03%) Ab & RNA unknown3 (3.61%)16 (11.68%) Active infection (RNA positive)15 (18.07%)19 (13.87%)Inflammatory cytokines (ng/mL) TNFα \[mean (SD)\]1.29 (0.58)1.51 (0.88)0.10 IL-6 \[mean (SD)\]0.04 (0.03)0.04 (0.03)0.11Bone turnover markers (ng/mL) P1NP \[mean (SD)\]0.52 (0.28)0.60 (0.30)**0.019** CTX \[mean (SD)\]0.30 (0.21)0.35 (0.19)**0.015**Bone mineral density (g/cm^2^) Weight bearing bones Lumbar spine \[mean (SD)\]1.29 (0.21)1.20 (0.21)**0.004** Total hip \[mean (SD)\]1.08 (0.16)1.02 (0.15)**0.009** Femoral neck \[mean (SD)\]1.15 (0.18)1.09 (0.17)**0.027** Non-weight bearing bones Distal radius \[mean (SD)\]0.84 (0.11)0.81 (0.14)0.27 Ultradistal radius \[mean (SD)\]0.45 (0.07)0.42 (0.09)**0.003**Sclerostin (ng/mL) \[mean (SD)\]0.25 (0.14)0.27 (0.16)0.71CD4 count (cells/mL)\
\[Median, Q1, Q3\]NA566\
(425, 762)NACD4 nadir (cells/mL)\
\[Median, Q1, Q3\]NA248\
(152, 367)NAHIV RNA viral load\
\[Median, Q1, Q3\]NA20\
(20, 120)NACumulative PI (years)\
\[Median, Q1, Q3\]NA3\
(0, 9.5)NACumulative NRTI (years)\
\[Median, Q1, Q3\]NA10\
(3, 13.5)NACumulative NNRTI (years)\
\[Median, Q1, Q3\]NA2.5\
(0, 6)NACumulative tenofovir disoproxil fumarate (TDF,years)\
\[Median, Q1, Q3\]NA2\
(0, 6.5)NACumulative abacavir (years)\
\[Median, Q1, Q3\]NA11\
(3.5, 15.5)NA[^1][^2]

3.2. Relationship between sclerostin and BMD {#s0050}
--------------------------------------------

Univariate modeling demonstrated significant positive associations (p \< 0.001) between sclerostin and BMD at all skeletal sites, indicating women with higher levels of sclerostin tended to have higher BMD ([Table 2](#t0010){ref-type="table"}). In nearly all skeletal sites, the associations between sclerostin and BMD were more significant than several known BMD-modifying variables, such as a HIV-serostatus, age, and BMI. Sclerostin was negatively associated with CTX (ρ = −0.138, p = 0.041) and positively associated with TNFα (ρ = 0.181, p = 0.007), but not statistically associated with P1NP and IL-6. Cumulative PI, NRTI, NNRTI, and abacavir exposure were not significantly associated with BMD ([Table 3](#t0015){ref-type="table"}). The associations between cumulative TDF and BMD were statistically significant in the lumbar spine and the ultradistal radius. No class of ART, including TDF, was statistically associated with circulating sclerostin levels ([Table 3](#t0015){ref-type="table"}).Table 2Univariate linear regression associations with bone mineral density among HIV-seropositive and seronegative WIHS participants.Table 2VariableWeight bearing bonesNon-weight bearing bonesLumbar spineTotal hipFemoral neckDistal radiusUltradistal radiusCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueSclerostin0.47\
(0.29, 0.64)\<0.0010.31\
(0.17, 0.44)\<0.0010.34\
(0.19, 0.49)\<0.0010.21\
(0.10, 0.33)\<0.0010.14\
(0.08, 0.22)\<0.001HIV Status−0.09\
(−0.15,−0.03)0.002−0.07\
(−0.11,−0.02)0.003−0.06\
(−0.11,−0.02)0.010−0.03\
(−0.06, 0.01)0.21−0.04\
(−0.06,−0.02)0.002Age\
(per 5-year)−0.04\
(−0.06,−0.01)0.010−0.02\
(−0.04, 0.01)0.064−0.01\
(−0.03, 0.01)0.40−0.01\
(−0.02, 0.02)0.77−0.01\
(−0.02, 0.01)0.11BMI\
(per 5-unit)0.04\
(0.01, 0.06)0.0030.05\
(0.03, 0.07)\<0.0010.04\
(0.02, 0.06)\<0.0010.03\
(0.02, 0.05)\<0.0010.03\
(0.02, 0.04)\<0.001Race:\
white vs black−0.06\
(−0.14, 0.02)0.13−0.05\
(−0.11, 0.01)0.10−0.09\
(−0.15,−0.02)0.013−0.07\
(−0.12,−0.02)0.010−0.04\
(−0.07,−0.01)0.026Race:\
other vs black−0.11\
(−0.19,−0.03)0.006−0.05\
(−0.11, 0.02)0.16−0.05\
(−0.12, 0.02)0.13−0.04\
(−0.09, 0.01)0.14−0.01\
(−0.04, 0.03)0.78Menopause−0.11\
(−0.17,−0.06)\<0.001−0.07\
(−0.11,−0.02)0.004−0.04\
(−0.09, 0.01)0.10−0.02\
(−0.07, 0.01)0.15−0.03\
(−0.05,−0.01)0.032IL-6−0.10\
(−0.96, 0.77)0.830.12\
(−0.54, 0.77)0.730.26\
(−0.47, 0.99)0.480.23\
(−0.32, 0.79)0.410.24\
(−0.11, 0.60)0.18TNFα−0.01\
(−0.04, 0.03)0.650.01\
(−0.02, 0.03)0.80−0.01\
(−0.04, 0.02)0.63−0.01\
(−0.03, 0.02)0.85−0.01\
(−0.03, 0.01)0.23PINP−0.18\
(−0.27,−0.08)\<0.001−0.13\
(−0.21,−0.06)\<0.001−0.11\
(−0.19,−0.03)0.005−0.07\
(−0.13,−0.01)0.021−0.07\
(−0.11,−0.04)\<0.001CTX−0.28\
(−0.42,−0.14)\<0.001−0.23\
(−0.33,−0.12)\<0.001−0.22\
(−0.34,−0.10)\<0.001−0.17\
(−0.26,−0.08)\<0.001−0.17\
(−0.22,−0.11)\<0.001Table 3Univariate associations between ART exposure and BMD and sclerostin among HIV positive participants.Table 3Variable\
(per month)Weight bearing bonesNon-weight bearing bonesSclerostinLumbar spineTotal hipFemoral NeckDistal radiusUltradistal radiusCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCumulative PI−0.02\
(−0.09, 0.06)0.660.01\
(−0.04, 0.06)0.66−0.03\
(−0.09, 0.02)0.24−0.04\
(−0.09, 0.01)0.12−0.01\
(−0.04, 0.03)0.77−0.02\
(−0.09, 0.06)0.66Cumulative NRTI−0.03\
(−0.10, 0.03)0.350.02\
(−0.03, 0.07)0.47−0.03\
(−0.08, 0.02)0.26−0.04\
(−0.08, 0.01)0.10−0.02\
(−0.04, 0.01)0.29−0.03\
(−0.10, 0.03)0.35Cumulative NNRTI−0.04\
(−0.13, 0.05)0.37−0.03\
(−0.09, 0.04)0.43−0.04\
(−0.11, 0.04)0.34−0.04\
(−0.10, 0.03)0.27−0.02\
(−0.07, 0.01)0.20−0.04\
(−0.13, 0.05)0.37Cumulative abacavir−0.03\
(−0.08, 0.03)0.320.02\
(−0.2 0.06)0.33−0.01\
(−0.05, 0.05)0.96−0.01\
(−0.05, 0.03)0.520.01\
(−0.02, 0.03)0.660.02\
(−0.02, 0.06)0.38Cumulative TDF−0.13\
(−0.23,−0.04)**0.008**−0.03\
(−0.11, 0.04)0.37−0.07\
(−0.15, 0.02)0.11−0.07\
(−0.14, 0.01)0.053−0.05\
(−0.09,−0.01)**0.043**−0.13\
(−0.23,−0.04)**0.008**[^3]

The positive associations between sclerostin and BMD at each site remained statistically significant in fully adjusted multivariate models ([Table 4](#t0020){ref-type="table"}). In each of the four models in [Table 4](#t0020){ref-type="table"}, the sclerostin regression coefficients were larger in the weight bearing BMD sites such as lumbar spine, total hip and femoral neck when compared to the non-weight bearing sites, such as distal and ultradistal radius. The regression coefficients between sclerostin and BMD were greater in HIV-seronegative women (Model 2 in [Table 4](#t0020){ref-type="table"}) compared to HIV-seropositives (Models 3 & 4 in [Table 4](#t0020){ref-type="table"}) in the weight bearing skeletal sites of the lumbar spine, total hip and femoral neck, and unchanged in the distal and ultradistal radius. In models restricted to women with HIV, adding cumulative TDF exposure did not attenuate the associations between sclerostin and BMD.Table 4Multivariate associations between sclerostin and BMD at various skeletal sites.Table 4Weight bearing bonesNon-weight bearing bonesLumbar spineTotal hipFemoral neckDistal radiusUltradistal radiusCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueCoefficient\
(95% CI)p-ValueTotal cohort (n = 212)Model 10.50\
(0.33, 0.68)\<**0.001**0.32\
(0.19, 0.44)\<**0.001**0.30\
(0.15, 0.45)\<**0.001**0.18\
(0.07, 0.30)**0.003**0.15\
(0.08, 0.21)\<**0.001**  HIV negative cohort (n = 80)Model 20.87\
(0.54, 1.19)\<**0.001**0.51\
(0.24, 0.79)\<**0.001**0.54\
(0.22, 0.85)**0.001**0.17\
(−0.09, 0.33)0.270.14\
(0.01, 0.26)**0.023**  HIV positive cohort (n = 132)Model 30.36\
(0.15, 0.57)**0.001**0.24\
(0.10, 0.39)\<**0.001**0.20\
(0.02, 0.38)**0.030**0.21\
(0.07, 0.36)**0.005**0.15\
(0.06,0.23)\<**0.001**Model 40.35\
(0.14, 0.56)**0.001**0.25\
(0.10, 0.39)**0.001**0.20\
(0.02, 0.38)**0.030**0.21\
(0.07, 0.36)**0.005**0.15\
(0.06, 0.23)**0.010**[^4][^5]

4. Discussion {#s0055}
=============

Our study investigated the relationship between circulating levels of sclerostin and BMD in HIV-seropositive and HIV-seronegative women. We demonstrated not only that higher circulating sclerostin is associated with higher BMD at several skeletal sites prone to fracture, but that these relationships are more statistically significant than are those of many known BMD-influencing factors, such as menopausal status and BMI. The association between sclerostin and BMD remained statistically significant in fully adjusted models, although the relationships were stronger in weight bearing skeletal sites when compared to non-weight bearing sites. Interestingly, the qualitatively attenuated model coefficients in HIV-seronegative (vs seropositive) women suggests a potential HIV-induced alteration in osteocyte expression of sclerostin, particularly in weight bearing skeletal sites.

Sclerostin is an osteocyte-derived antagonist to the Wnt/β-catenin signaling pathway ([@bb0120]). Wnt/β-catenin signaling is inhibited due to HIV-infection ([@bb0010]) and HIV viral proteins inhibit osteoblast function, in part, through Wnt inhibition ([@bb0045]). Therefore, increased sclerostin expression and the subsequent inhibition of Wnt/β-catenin signaling may be a potential mechanism by which HIV infection could cause bone loss. However, the only other study to compare sclerostin levels according to HIV-serostatus reported that HIV-seropositive ART-naive men and women had lower circulating sclerostin than did HIV-seronegatives ([@bb0015]). In contrast to the results from [@bb0015], we found no difference in the levels of circulating sclerostin when comparing HIV-seropositives to HIV-seronegatives. The reason for this discrepancy could be due to many factors. Our cohort included only women that were in peri- and early postmenopause and most of the HIV seropositive women were on ART. The average age of women in our study was 49 years compared to 38 years in the other ([@bb0015]); sclerostin levels are highly associated with age ([@bb0140]; [@bb0020]), which we confirm in our study.

Despite the bone formation suppressing function of sclerostin ([@bb0025]; [@bb0030]; [@bb0125]), it has been well-established that higher circulating sclerostin levels are associated with increased BMD, including in a cohort of HIV-seropositive participants ([@bb0080]). The reason for this seeming contradiction may be due to the timing of the sclerostin measurements. Morse et al. ([@bb0155]) investigated sclerostin concentrations in spinal cord injury (SCI) patients, a clinical situation where an incident injury triggers rapid bone loss, and proposed a phasic sclerostin reponse. In SCI, they suggested that there is an early acute elevation of sclerostin, which likely represents its mechanistic role in suppressing bone formation, followed by a chronic phase where sclerostin levels are lowered and become more indicative of sclerostin\'s role as a biomarker of BMD ([@bb0155]). After stabilization, sclerostin levels likely reflect the number of osteocytes ([@bb0050]; [@bb0055]), the bone cell responsible for the production of sclerostin.

The potential reduction in the association between sclerostin and BMD in HIV-seropositive participants compared to HIV-seronegatives, while not statistically significant, may suggest HIV-induced alterations to osteocyte physiology. However, in the current study, we found no HIV-serostatus differences in the amount of circulating sclerostin, despite a clear reduction in bone mass in HIV-seropositives, which is generally associated with a reduction in sclerostin. Therefore, it is possible that HIV infection induces an increase in the amount of sclerostin produced per osteocyte. Mödder et al. ([@bb0145]) came to a similar conclusion with respect to age when comparing the association between sclerostin and BMD in aging cohorts, suggesting that with aging, there is an increase in the production of sclerostin per individual osteocyte. Although HIV ([@bb0090]) and viral products ([@bb0070]) have been shown to alter osteoblast physiology, it remains to be determined whether osteocytes, which are terminally differentiated osteoblasts, are similarly affected by HIV, especially in the ART era where there is maximum viral suppression and little to no-viral proteins secreted.

We also found that the association between sclerostin and BMD, at least qualitatively, varied according to the skeletal site assessed. Specifically, the associations were stronger in the weight bearing skeletal sites of the lumbar spine, total hip, and femoral neck, when compared to the non-weight bearing skeletal sites of the distal and ultradistal radius, a finding which is consistent with reports in a population cohort of men and women participants ([@bb0145]). The skeletal sites that were most highly associated with sclerostin levels were those with considerable trabecular bone, which may indicate that sclerostin levels are more sensitive to trabecular bone parameters, a finding consistent with published reports in haemodialysis patients ([@bb0050]).

Initiation of ART is reported to cause bone mass losses ([@bb0035]). TDF in particular, is associated with a greater reduction in BMD within the first year of initiation when compared to non-TDF containing ART regiments ([@bb0100]). Switching from TDF to abacavir leads to increased circulating sclerostin levels ([@bb0165]) and moderately increased BMD ([@bb0160]). In the current study, TDF use was associated with reduced BMD, while the association between abacavir and BMD was not statistically significant. There were no associations of either TDF or abacavir with sclerostin. Due to the association between TDF and BMD, we included cumulative TDF in fully adjusted models and found no effect on the relationship between sclerostin and BMD, suggesting that in the current cohort, any effects of TDF on bone are independent of sclerostin.

This study is the first to assess the association between sclerostin and BMD according to HIV-serostatus. Among its strengths were that the cohort included postmenopausal women, a group at particularly high risk for osteoporosis. The study limitations include the use of a single sex cohort and therefore, the results may not be generalizable to men, and that sclerostin and bone density measures were only available at one time point so longitudinal trends could not be evaluated. There have been several studies comparing the validity of commercially available ELISA assays to measure circulating sclerostin and we chose the TECOmedical assay due to its consistently good performance characteristics ([@bb0060]; [@bb0170]). Additionally, the TECOmedical assay is able to detect sclerostin in the sodium citrate stabilized plasma samples used in this study. Although EDTA stabilized plasma is considered the preferred matrix for measuring circulating sclerostin, its performance in sodium citrate stabilized plasma has not been reported. Further, it is possible that the TECOmedical assay also detected sclerostin fragments, so we cannot confirm that all of the sclerostin measured is indeed biologically active ([@bb0060]).

As PLWH age, there is an increased prevalence of HIV-associated co-morbidities, including low BMD. Understanding mechanism(s) that drive bone loss are critical to inform therapeutic strategies to ameliorate and/or reduce the risk of bone loss and associated fracture risks. These mechanisms may or may not be HIV-specific. Indeed, we report here that Wnt/β-catenin signaling as assessed by circulating sclerostin could be a potential biomarker for bone mass, independent of HIV status. However, the reduction in model estimate as a function of HIV-serostatus may point to an increased per cell production of sclerostin in HIV-seropositive women. As such, agents that activate Wnt/β-catenin signaling in bone may serve as viable therapeutic approach to reduce and/or protect against bone loss among aging individuals, including in PLWH.

Transparency document {#s0060}
=====================

Transparency documentImage 1

CRediT authorship contribution statement {#s0070}
========================================

**Ryan D. Ross:**Conceptualization, Investigation, Data curation, Writing - original draft, Writing - review & editing, Project administration, Funding acquisition. **Anjali Sharma:**Conceptualization, Methodology, Writing - review & editing, Funding acquisition. **Qiuhu Shi:**Methodology, Data curation, Formal analysis, Writing - review & editing. **Donald R. Hoover:**Conceptualization, Methodology, Formal analysis, Writing - review & editing. **Kathleen M. Weber:**Conceptualization, Writing - review & editing, Funding acquisition. **Phyllis C. Tien:**Conceptualization, Writing - review & editing, Funding acquisition. **Audrey L. French:**Conceptualization, Writing - review & editing, Funding acquisition. **Lena Al-Harthi:**Conceptualization, Writing - review & editing, Funding acquisition. **Michael T. Yin:**Conceptualization, Methodology, Writing - review & editing, Project administration, Funding acquisition.

The authors would like to thank the participants in the WIHS cohort study who participated in the MSK study. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). Data in this manuscript were collected by the Women\'s Interagency HIV Study, now the MACS/WIHS Combined Cohort Study (MWCCS); additional biomarker testing and data analyses for this manuscript were supported by National Institute Of Allergy And Infectious Diseases (NIAID) funding to the Chicago WIHS; 5U01AI034992-24 (Mardge Cohen, Audrey French). WIHS/MWCCS (Principal Investigators) for this project/manuscript include: Bronx CRS (Kathryn Anastos and Anjali Sharma), U01-HL146204; U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146240; Connie Wofsy Women\'s HIV Study, Northern California CRS (Bradley Aouizerat and Phyllis Tien), U01-HL146242; Data and biomarkers for this manuscript were supported by funding from 10.13039/100000060National Institute Of Allergy And Infectious Diseases (NIAID); the MWCCS is funded primarily by the 10.13039/100000050National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the 10.13039/100009633Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), 10.13039/100000060National Institute Of Allergy And Infectious Diseases (NIAID), 10.13039/100000051National Human Genome Research Institute (NHGRI), 10.13039/100000049National Institute On Aging (NIA), 10.13039/100000072National Institute Of Dental & Craniofacial Research (NIDCR), 10.13039/100000060National Institute Of Allergy And Infectious Diseases (NIAID), 10.13039/100000065National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Mental Health (NIMH), National Institute On Drug Abuse (NIDA), 10.13039/100000056National Institute Of Nursing Research (NINR), 10.13039/100000054National Cancer Institute (NCI), 10.13039/100000027National Institute on Alcohol Abuse and Alcoholism (NIAAA), 10.13039/100000055National Institute on Deafness and Other Communication Disorders (NIDCD), 10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Additional support was provided by the Rush University Scientific Leadership Council via a musculoskeletal pilot grant (RDR), the 10.13039/100000002National Institutes of Health through Grants AI059884 (MTY), AR061993 (AS) and the 10.13039/100006108National Center for Advancing Translation Sciences, through Grant Number UL1TR001873.

The [Transparency document](http://dx.doi.org/10.1016/j.bonr.2020.100279){#ir0005} associated with this article can be found, in online version.

[^1]: Abbreviations: BMI - body mass index, Ab - antibody, TNFα - tumor necrosis factor α, IL-6 - interleukin 6, P1NP - Procollagen type 1 N-terminal propeptide, CTX -- C-telopeptide of type I collagen.

[^2]: Bolded values indicate p\<0.05.

[^3]: Bolded values indicate p\<0.05.

[^4]: Model 1 adjusts for HIV status, age, BMI, race, site and CTX. Model 2 adjusted for age, BMI, race, site, and CTX. Model 3 adjusts for age, BMI, race site, CTX, and cumulative Tenofovir.

[^5]: Bolded values indicate p\<0.05.
